TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 39 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified GD-T cell product line - phase IIb/III pivotal trial in treatment of AML using its allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product candidate, OmnImmune is an unmodified allogeneic GD-T cell product, being initially used for the treatment of AML. Its pre-clinical stage program is focused on developing CAR-modified allogeneic GD-T cell products targeting solid and hematological indications. The company has an Israeli patent and Japanese patent applications covering the method of preparing and using GD-T cells in the allogeneic treatment of subjects suffering from viral, fungal and protozoal infections or cancer.
Follow-Up Questions
Qui est le CEO de TC Biopharm (Holdings) PLC ?
Mr. Bryan Kobel est le Chief Executive Officer de TC Biopharm (Holdings) PLC, il a rejoint l'entreprise depuis 2021.
Quelle est la performance du prix de l'action TCBPY ?
Le prix actuel de TCBPY est de $0.28, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de TC Biopharm (Holdings) PLC ?
TC Biopharm (Holdings) PLC appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de TC Biopharm (Holdings) PLC ?
La capitalisation boursière actuelle de TC Biopharm (Holdings) PLC est de $2.8M
Est-ce que TC Biopharm (Holdings) PLC est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour TC Biopharm (Holdings) PLC, y compris 3 achat fort, 5 achat, 1 maintien, 0 vente et 3 vente forte
